<DOC>
	<DOCNO>NCT00413218</DOCNO>
	<brief_summary>The purpose study compare safety efficacy Isavuconazole versus caspofungin follow voriconazole treatment candidemia invasive Candida infection .</brief_summary>
	<brief_title>Isavuconazole ( BAL8557 ) Treatment Candidemia Other Invasive Candida Infections</brief_title>
	<detailed_description>Candida infection , represent approximately 80 % major systemic fungal infection , fourth common cause nosocomial bloodstream infection , mortality rate 40 % . Isavuconazole yet approve treatment fungal infection . This study investigate efficacy safety intravenous oral Isavuconazole . Patients randomized Isavuconazole reference regimen . Patients positive blood- deep tissue culture candida fungi include .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients candidemia invasive Candida infection Presence fever , hypothermia appropriate local sign infection Female patient must nonlactating risk pregnancy Patients sole diagnosis mucocutaneous candidiasis , i.e . oropharyngeal , esophageal genital candidiasis ; candidal low urinary tract infection Candida isolate solely respiratory tract specimens Patients candidemia fail previous antifungal therapy infection Patients previously enrol phase III study isavuconazole Patients body weight &lt; 40kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Phase III study</keyword>
	<keyword>Isavuconazole</keyword>
	<keyword>Candidemia</keyword>
	<keyword>Invasive Candida infection</keyword>
	<keyword>Candidemia invasive candida infection</keyword>
	<keyword>ASP9766</keyword>
	<keyword>BAL8557</keyword>
</DOC>